arrow_back Back Filing freshness 20-F FY 2025 SEC EDGAR

Adagene Inc.

ADAG
$4.15 ▲ +0.03 (+0.73%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
9 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
26
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

Adagene Inc. faces fundamental challenges with weakness in Return on Common Equity (%). On the positive side, Debt to Equity remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $244.9M
Dividend Yield
Revenue Growth 7332.8%
Op. Margin -279.5%
ROIC -57.8%
FCF / Share $-0.27
Trailing P/E
Price / Book 7.0x
FCF Yield
Debt / Equity 0.03
info Valuation on last close. End-of-day price, Aug 7, 2026.

9-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$7.67M
↑ +7332.8%
Net Income Profit after all expenses
$-17.61M
↑ +47.3%
Operating Margin Operating profit as % of sales
-279.5%
↓ -113.4% 0th
FCF / Share Free cash flow per share
$-0.27
↑ +49.7%
Long-Term Debt Long-term obligations
$1.14M
↑ +172.7%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
17
Financial Health
54
Cash Quality
60

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 9 quarters